Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug withdrawals and the lessons within.

Dennis A Smith1, Esther F Schmid

  • 1Pfizer Global Research and Development, Sandwich Laboratories, Sandwich, Kent, CT13 9NJ, UK. dennis.a.smith@pfizer.com

Current Opinion in Drug Discovery & Development
|February 1, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Total drug's last stand on phospholipidosis: Unbound drug rules!

Drug metabolism and disposition: the biological fate of chemicals·2025
Same author

Free Drug Concepts: A Lingering Problem in Drug Discovery.

Journal of medicinal chemistry·2025
Same author

Teratogenicity is more likely a function of primary and secondary pharmacology than caused by chemically reactive metabolites: a critical evaluation of 40 years of scientific research.

Xenobiotica; the fate of foreign compounds in biological systems·2024
Same author

Through a computer monitor darkly: artificial intelligence in absorption, distribution, metabolism and excretion science.

Xenobiotica; the fate of foreign compounds in biological systems·2023
Same author

Anti-infectives Developed as Racemic Drugs in the 21st Century: Norm or Exception?

ACS medicinal chemistry letters·2023
Same author

Ring-fused dimethoxybenzimidazole-benzimidazolequinone (DMBBQ): tunable halogenation and quinone formation using NaX/Oxone.

Organic & biomolecular chemistry·2021
Same journal

Microreactors for continuous processing – How close to commercial utility?

Current opinion in drug discovery & development·2010
Same journal

Synthesis of polyketide natural products and analogs as promising anticancer agents.

Current opinion in drug discovery & development·2010
Same journal

Enantioselective synthesis of substituted oxindoles and spirooxindoles with applications in drug discovery.

Current opinion in drug discovery & development·2010
Same journal

Eliminating pharmaceutical impurities: Recent advances in detection techniques.

Current opinion in drug discovery & development·2010
Same journal

Stereoselective heterocycle synthesis through oxidative carbon-hydrogen bond activation.

Current opinion in drug discovery & development·2010
Same journal

Catalysis in aqueous media for the synthesis of drug-like molecules.

Current opinion in drug discovery & development·2010
See all related articles

Drug withdrawals due to specific receptor interactions can be addressed by improved screening. Complex toxicity mechanisms remain challenging for drug discovery programs and risk assessment.

Area of Science:

  • Pharmacology
  • Drug Discovery
  • Toxicology

Background:

  • Recent decades have seen significant drug withdrawals impacting pharmaceutical research and development.
  • Withdrawals often stem from drug interactions with biological targets (primary or secondary pharmacology).
  • Complex mechanisms like organ toxicity pose challenges for predictive screening and risk assessment.

Purpose of the Study:

  • To classify drugs withdrawn from the US market over the last 25 years based on their reasons for withdrawal.
  • To examine how drug discovery programs have evolved in response to these withdrawal events.
  • To analyze the impact of withdrawal reasons on the design of drug targets and screening programs.

Main Methods:

  • Classification of withdrawn drugs by their specific reasons for market withdrawal.

Related Experiment Videos

  • Analysis of the relationship between withdrawal mechanisms and drug discovery methodologies.
  • Review of changes in drug target identification and screening program design.

    • Main Results:

    • Drugs withdrawn due to simple, reversible interactions with single targets are identifiable through validated screening.
    • Complex mechanisms, such as organ toxicity, present difficulties in developing effective screening methods and extrapolating risks.
    • Drug discovery strategies have been modified to better predict and mitigate withdrawal-related issues.

    Conclusions:

    • Understanding the specific pharmacology leading to drug withdrawal is crucial for improving preclinical screening.
    • Addressing complex toxicological mechanisms requires innovative approaches in drug discovery and risk assessment.
    • The analysis of past withdrawals informs the future design of safer and more effective drug development programs.